(at least 50% reduction in seizure frequency) in double-blind, placebo-controlled trials in Lennox-Gastaut syndrome
| Seizure type | Felbamate vs. Placebo | Lamotrigine vs. Placebo | Topiramate vs. Placebo |
|---|---|---|---|
| Total seizures | 50% vs. 11%* | ||
| All major seizures (drop attacks plus tonic-clonic) | 33% vs. 16%* | 33% vs. 8%* | |
| Drop attack or atonic seizures | 57% vs. 9%* | 37* vs. 22%* | 28% vs. 14% |
| Tonic-clonic seizures | 60% vs. 23%* | 43% vs. 20%* |
*P < .05
Adapted from: Glauser TA and Morita DA. Lennox-Gastaut syndrome. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;73. With permission from Elsevier (www.elsevier.com).
Reviewed By:
Steven C. Schachter MD
on:
Friday, April 30, 2004
